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A B S T R A C T
Background and Purpose: Primary neuroendocrine breast carcinomas (NEBC) are uncommon lesions;
they constitute approximately 1% of all breast cancers and mostly affect elderly patients. According
to the most recent World Health Organization classiﬁcation, it concerns almost exclusively the female
population between the sixth and seventh decades. The aim of this retrospective study is to analyze the
clinicopathological aspects of 96 NEBC patients who had undergone surgical resection at a single institute.
Methods: We retrospectively analyzed a series of 96 patients who underwent surgical resection for NEBC
between January 1992 and August 2013.
Results: The 96 patients with NEBC were divided into two categories: 61 (63.5%) in whom the expression
of a neuroendocrine marker was present in more than 50% of neoplastic cells and 35 (36.5%) with a minor
neuroendocrine component. Our data show a mean age of the patients at diagnosis of 70 years (range 42–87
years); the 10-year survival of the 96 patients was 87%, moreover we report tumor location, type of surgical
operation, tumor size (average 2.1 cm), hormone therapy, chemotherapy and radiotherapy if used, recurrence
sites, overall and disease free survival times.
Conclusions: This study showed a better prognosis in patients with NEBC compared with breast carcinomas
with a minor neuroendocrine component and with conventional invasive ductal or lobular cancers.
© 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
1. Introduction
Neuroendocrine breast carcinomas (NEBC) include an heterogeneous
group of tumors, showing morphological features similar to those
of neuroendocrine tumors of the gut and lung, and expressing
one or more neuroendocrine markers in at least 50% of tumor
cells. NEBC are rare lesions, representing about 1% of all breast
cancers (BC), and according to World Health Organization (WHO)
data mostly affect elderly patients. 1 Except for its small-cell variant,
NEBC is characterized by less aggressiveness than the invasive ductal
variant of BC.
In the international scientiﬁc literature the ﬁrst description of
BC morphologically similar to intestinal carcinoids dates back to
1963 and is attributed to Feyrter and Hartmann. 2 On the basis of
argentic impregnation, Feyrter and Hartmann suggested the nature of
endocrine “mucoid” carcinoma of the breast. However, it is commonly
accepted that the ﬁrst histopathological classiﬁcation of NEBC,
together with a clinical and prognostic analysis, is to be attributed to
two American pathologists: Antonio Cubilla and James Woodruff in
1977. 3 They published a series of 8 cases sharing peculiar cytological
characteristics, such as a microscopic appearance comparable to
intestinal carcinoid, a positive staining for Grimelius coloration and
a neurosecretory structure at the electron microscope.
Because of the work of Cubilla and Woodruff on NEBC, this
cancer has been identiﬁed by some authors as “carcinoid of Cubilla
and Woodruff”. This name was progressively abandoned, until the
deﬁnitive taxonomic proposal of neuroendocrine breast cancer. 1,4
Since 2003, WHO deﬁnes NEBC as a separate entity, 1 consisting
of a heterogeneous group of breast primitive tumors of epithelial
origin and morphology, similar to gastrointestinal and pulmonary
neuroendocrine tumors, expressing a neuroendocrine marker 1 in
at least 50% of the total cell population. In fact, a focal neuroendocrine
differentiation is observed in a large number of breast cancers:
according to statistics, it may be represented in 10–18% of BC. 1,4–7
It can be found in many breast histotypes, such as ductal, NOS,
lobular, 1,8 mucinous, tubular and papillary breast cancers. 9
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The diagnosis of NEBC needs immunohistochemistry (HIC) positiv-
ity in at least 50% of the followingmarkers in the tumor population:
– chromogranin (Cg): although their hormonal function is not
precisely known, 10 Cgs are the most represented proteins in
the granules of neurosecretion, where they can reach 80% of
the total proteins. 11 Cgs were initially identiﬁed in the adrenal
medulla, 12 after they had been found in endocrine tissues and
in the brain. Their expression in neoplastic tissue, however, is
related to the grading of the tumor, with less expression in
poorly differentiated carcinomas. 13 CgA is the most sensitive
neuroendocrine marker 14: it consists of 439 amino acids and it is
usually bound by the monoclonal antibody LK2H10, which confers
high diagnostic reliability. The advent of immunohistochemical
staining, thanks to the work of Bussolati et al. 15 in 1985, gave
new support to the theory of the presence of cells belonging
to the diffuse neuroendocrine system in the normal mammary
epithelium. In fact, according to the authors, CgA can be present
even in non-neoplastic tissue samples. CgB and secretogranin II are
less speciﬁc than CgA for normal and neoplastic endocrine tissue;
– synaptophysin (Syn): this is a cytoplasmic glycoprotein composed
of 313 amino acids, involved in synaptic transmission and expressed
by almost all neuronal and neuroendocrine cells. It is one of the
most reliable neuroendocrine tumor markers 6;
– neuron-speciﬁc enolase (NSE): this is an isoform of enolase, selec-
tively expressed in neurons and endocrine cells. It is occasionally
HIC positive in NEBC 16;
– CD56: this is a typical adhesion protein of neuronal cells; if detected
by a speciﬁc monoclonal antibody, it can act as a neuroendocrine
marker, but it is considered to be statistically less sensitive and
less speciﬁc, thus playing a minor role compared to the markers
mentioned above. 17
Moreover, NEBC can be diagnosed by the presence of secretory
granules by electron microscope, although this is an instrument
rarely used in clinical practice. Ultrastructural analysis shows the
NEBC differentiation 18 by the presence of electron-dense scattered
intracytoplasmic granules. 19 These granules have a clear peripheral
ring and a central electron-dense core, with a strong dimensional
variability 20 (range 150–450nm). Moreover, they appear in small
vesicles, structures derived from the Golgi apparatus, positioning
most of the time close to the nucleus.
In breast pathology no debate has reached such a high number
of dissenting voices as the acceptance of NEBC being a primitive
mammary tumor. One reason is the absence of endocrine cells in
the normal breast tissue, 8 both fetal and adult, although in 1947 the
German pathologist Vogler 21 demonstrated their presence along the
ductal epithelium: an event, anyway, considered rare even by Volger
and the subsequent supporters of this theory. 2,3,22–24 They based
this pathogenic theory on the wide distribution of argyrophilic cells
in the body. In fact, endocrine cells (APUD cells) were progressively
identiﬁed in extra-intestinal sites such as the lungs, 25,26 thymus, 27
gallbladder, skin, 28 ovary and testis. 29,30 It would then be likely
that they could also occur sporadically in the breast. In 1985, this
theory found the ﬁrst immunohistochemical conﬁrmation: Bussolati
et al. 15 demonstrated CgA-positive cells in normal breast ducts.
However, other authors 8,23 have not conﬁrmed the presence of this
cell differentiation in the breast parenchyma, fueling the controversy
about the origin of the NEBC.
In parallel with this theory, however, there is the belief that NEBC
originates – like any other histological type – from a primitive
stem cell that differs along a line of ductal type (standard or
special) or lobular type. Among the ﬁrst studies in this direction we
remember the study of Capella et al. 20 in 1990, which highlights
the simultaneous presence of exocrine granules (mucinous) and
endocrine effects in the context of breast cancer – a feature highly
indicative of a common stem cell between the neuroendocrine and
mucinous carcinoma. The epithelial cells should acquire then, during
the process of carcinogenesis, the ability of differentiation, focal or
diffused, towards a different histological line.
Among the studies in support of this hypothesis, it is worth
mentioning the work of Perou et al. 31 in 2000, that gave birth to
a different analytical approach to BC. Perou has indeed shifted the
attention to themolecular analysis, setting the stage for the biological
classiﬁcation (cancer subtypes Luminal A, Luminal B, HER2+, Basal-
like) on which actual BC treatments are based. Developing Perou’s
studies, Weigelt et al. 32 have investigated gene expression analysis
using DNA-microarrays on special histological types of BC. It is
interesting to report the results obtained on NEBC, which show
important similarities with the mucinous carcinoma. In fact, starting
from a stem cell, the carcinogenic process determines transcriptional
mutations, genetic and epigenetic, common to NEBC and mucinous
carcinoma (in particular subtype B, or “hypercellular”, originally
classiﬁed by Capella et al. 33) with respect to ductal carcinoma.
These mutations cause an overproduction of protein, conﬁrmed
by immunohistochemical analysis, which gives a speciﬁc biological
behavior to this cancer. In particular, in the case of NEBC, compared
with the same grading of ductal BC with Luminal A phenotype,
genes coding for the chromogranins, synaptophysin, CD56, bombesin,
metalloproteases and collagenases are ampliﬁed. Similarly, the genes
FOXA1, XBP1, ERBB4 are up-regulated; these genes determine the
expression of estrogen receptors, progesterone, and in 45% of cases,
androgen. Down-regulation, instead, appears for gene networks
involved in migration, invasion and proliferation; similarly the
expression of high molecular weight cytokeratins is also decreased.
To date only one case of NEBC demonstrating positivity for
cytokeratins basal-type has been reported, and this was a small-cell
variant. 34 These genetic characteristics are reﬂected in the biological
and immunohistochemical NEBC characteristics; in fact it is classiﬁed
within the Luminal biological subtype. 35
Epidemiologically, the incidence of NEBC appears to be controver-
sial. According to the most recent WHO classiﬁcation, similar to the
more frequent breast cancers, NEBC almost exclusively affects female
patients aged between the sixth and seventh decade 1,36; few cases
are therefore diagnosed in the premenopausal period. 37 Currently
approximately 200 cases have been described in the literature, in the
form of small series 3,5,6,24,36–41 or as individual case reports, one of
them in the bilateral type. 3,42 A few cases in males have also been
reported. 43–46
Data related to the incidence of NEBC showed different per-
centages: from rare observations (0.09%) in the review by Fisher
et al. (1979) 24 in a series of 3,300 BC, to slightly higher according
to Günhan-Bilgen et al. (2003) where they represent 0.27% of
1,845 BC cases, 47 to Lopez-Bonet et al. (2008) reporting 0.51% of
1,368 patients. 38 The WHO conﬁrms the incidence of NEBC as <1%,
while, as far as concerns a focal representation within invasive
carcinomas, the percentage increases to 10–18%. 1 With regard to
the rare anaplastic small-cell variant, the ﬁrst case was reported in
1983, 48 and up to now about 40 cases have been described 49–52; of
these, the largest series published includes 9 patients. 49
The clinical presentation of NEBC has features comparable to
those of more common forms of BC. In fact, mammographically it is
substantially similar to the other malignant lesions. In the literature,
although NEBC is described in some small series and numerous
case reports, only three publications 47,48,53 provide an analysis
of NEBC imaging. They agree on its mammographic appearance;
in fact it often appears as a dense mass, predominantly with
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speculated or lobulatedmargins. According to someauthors, 54,55 pre-
surgery diagnosis of NEBC by ﬁne-needle aspiration cytology (FNAC)
is possible, though not without difﬁculty. May–Grünwald–Giemsa
staining showsmoderate cellularity, low cohesiveness, with elements
of polygonal shape and plasmacytoid, with abundant cytoplasm, oval
nuclei and small nucleoli. Also, there is poor dimensional variation
between the cell elements, but the decisive factor in the FNAC
diagnosis appears to be the presence of cytoplasmic azurophilic
granules, in particular in the cell periphery. 56 More frequently,
authors report histological identiﬁcation of NEBC by aspiration core
biopsy. 37,42,44,54,57 At present, however, such a diagnosis does not
determine a treatment divergent from that of other histological
types of BC. Compared to histologically different BCs, a peculiarity
of NEBC is the occurrence of clinical conditions related to hormonal
hypersecretion, although extremely rare. In fact, patients with symp-
toms related to ectopic secretion of ACTH, 58 parathyroid hormone,
prolactin, norepinephrine and calcitonin are described. 59,60 These
clinical presentations, however, are now considered exceptional and
related to advanced tumor stages. These stages of diagnosis have
decreased in the last decade, due to the diagnostic anticipation pro-
duced by the increasingly wide spread of mammographic screening.
Peculiar is the case report of a patient in whom a carcinoid crisis
is described, induced by compression during mammography of the
mammary gland, site of metastasis from ileal carcinoid. 61
2. Patients and methods
We retrospectively reviewed a series of 2829 BC patients who un-
derwent surgery between January 1992 and August 2013. There were
96 patients with neuroendocrine breast cancer (NEBC) or a focally
expressed neuroendocrine component in the context of a different
histological type (NEF). Survival analysis of entire sample considered
the following variables: age, gender, histology, tumor diameter, tumor
grade, number of lymph nodes involved, expression of hormone
receptors, c-erbB2, Ki-67 proliferation index, oncoprotein p53 and
type of surgical treatment (conservative/mastectomy, lymph nodes).
We ﬁnally conducted bivariate analysis to identify factors associated
with histotype NE.
3. Results
Wedivided the 96 patientswith NEBC components into two groups:
– 61 (63.5%) NEBC, in whom the expression of a neuroendocrine
marker was present in more than 50% of neoplastic cells.
– 35 (36.5%) NEF, carcinomas in which the expression of neuroen-
docrine markers was found in less than 50% of the tumor cells.
The cohort under consideration consists of 95 female patients and
1 male patient (inﬁltrating ductal carcinoma [IDC] + focal expression
NEBC). The average age at the time of diagnosis was 70.1 years (range
40–94 years) and the median follow up was 65 months (range 2–242
months).
These two groupswere analyzed separately in order to decrease the
histological heterogeneity.
3.1. Primary neuroendocrine carcinomas (NEBC)
NEBC constitute 63.5% of all neuroendocrine carcinomas analyzed
(n =61). According to histological examination they were divided into
NEBC solid type (n = 29), NEBC solid aspects mucinous type B (n =14),
micro-invasive NEBC (n =6), NEBC solid associated with a second
nodule of IDC or DCIS (n =5), NEBC solid with focal component of
DCIS (n =3), NEBC solid with focal component of IDC (n =1), and
Fig. 1. Different histological types of NEBC present in our series.
ﬁnally, with respect to anaplastic variants, large-cell NEBC (n =2) and
small-cell NEBC (n =1). In order to standardize the categories of NEBC
analyzed, anaplastic carcinomas (n =3) were evaluated separately
from the remaining 58 NEBC (Fig. 1).
The neuroendocrine carcinomas of solid type had the following
clinical characteristics: the enrolled patients had a mean age at
diagnosis of 70 years (range 42–87 years), mainly (90.5%) in patients
in menopause (on average menarche has risen to 13 years and
menopause to 48 years) with an average BMI of 26 kg/m2. On average,
they had 1.7 child per patient, with breast-feeding in 54% of cases.
Some degree of family history of breast cancer was present in 27% of
patients.
The laterality of the tumor was left breast in 50% of cases, right
breast in 46.6%, and bilateral in 3.4% (n =2, where histological
examination of the contralateral nodule showed IDC in one case, and
IDC with focal expression NE in the other).
Surgical therapy was performed as follows:
– 4 tumorectomies (including 1 followed by further lumpectomy,
quadrantectomy and ﬁnally ipsilateral mastectomy, while in 1 case
just quadrantectomy of completion);
– 26 quadrantectomies (including 1 for lumpectomy followed by
recurrence, 1 contralateral quadrantectomy, 1 for contralateral
cancer treated with medical therapy alone);
– 29 mastectomies (28 ab initio and 1 after quadrantectomy).
Furthermore, the surgical treatment of axilla we performed
included:
– 16 patients who underwent sentinel lymph node biopsy (SLNB),
followed in only 1 by axillary lymph node dissection due to the
presence ofmetastasis in the SLN (3 levels of lymph nodes removed
were found to be negative for neoplastic cells);
– 33 patients who underwent axillary lymph node dissection,
without looking for the sentinel lymph node;
– 9 patients who did not receive any surgical treatment of the
axilla (including 1 for previous ipsilateral axillary lymph node
dissection).
Finally, related to the clinical presentation of the NEBC, in our series
there was a high correspondence between the dimensional descrip-
tion of the echo-mammographic imaging (MRIwas performed in only
one case) and the subsequent deﬁnitive histological detection.
In just one patient the preoperative tumor markers were found
to be signiﬁcantly increased (CA15-3 = 193U/mL). Two patients had
staging exams positive for distant metastases (bone metastases in
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bone scintigraphy), but in these two cases the values of the pre-
operative tumor markers are not available.
The pathological characteristics of the NE carcinomas analyzed can
be summarized as follows:
– The focality was unifocal in 77% of cases (n =47), bifocal in
14.7% (n =9) and multifocal in 3.3% (n = 2).
– Histological grade reported was G1 in 34% of cases, G2 in 64% and
G3 in 2%.
– Average tumor diameter was 2.05 cm (range 0.6–6 cm), determin-
ing a pT1a = 0%, pT1b = 17.2% (n =10), pT1c = 43.1% (n =25),
overall pT1 = 60.3% (n =35); pT2 = 34.5% (n =20), pT3 = 1.7% (n =1),
pT4a = 0% and pT4b = 3.4% (n =2).
– With regard to lymph node involvement, if axillary surgery
performed, there were pN0 = 76.6% of cases (n =36), pN1 = 21.3%
(n =10), pN2 = 0% and pN3 = 2.1% (n =1).
Receptor expression can be summarized as follows:
– Estrogen receptor (ER) was present in 90% of carcinomas, with an
expressiveness average of 87%, while the progesterone receptor
(PgR) of 75%;
– The proliferation index Ki-67 average was overexpressed in 14% of
cells, with a range of 0% to 39%;
– The growth factor receptor c-erbB2was virtually absent (in only one
case it was overexpressed in 15% of the cell population);
– The p53 tumor suppressor gene was overexpressed, on average,
only in 2% of the neoplastic cells (range 0–20%).
As regards post-operative treatment, adjuvant chemotherapy was
administered in 5% of cases (n =6), radiotherapy in 48% (n = 27),
and hormone therapy in 75% (n =42), with some patients receiving
multimodal treatment.
The median follow up of the NEBC patients was 88 months (range
4–242 months), with pathological ﬁndings (for neoplastic recurrence
or any other neoplastic disease) in 19.7% of cases (n = 12). Speciﬁcally,
local or systemic recurrence occurred in 14.8% of patients (n = 9)
after a median time of 53.7 months (range 8–120 months), while
the onset of a different cancer was recorded in 4.9% (n =3), including
a contralateral breast cancer and uterine cancer in one patient, and
contralateral breast tumor in two patients.
Recurrences of the solid type of NEBC (n =9) occurred in the same
breast in 33% of cases (n =3), as liver metastases in 44% (n =4), as
bone metastases in 66% (n =6), with brain localization in 11% (n =1)
and with lymphnodal distant dissemination in 33% of cases (n =3). Of
these patients, 7 (78%) died from cancer cachexia, 1 (11%) died from
liver metastases, and 1 (11%) is still alive after a lumpectomy of breast
recurrence and subsequent hormone therapy.
3.2. Carcinomas with focal neuroendocrine component
These constitute 36.5% of neuroendocrine carcinomas analyzed
(n =35). Focal expression of neuroendocrine cancer was associ-
ated with mucinous carcinoma (n =4), intraductal papillary car-
cinoma (n =1), ductal-lobular carcinoma (n =1), ductal carcinoma
in situ (n =1), and predominantly with inﬁltrating ductal carci-
noma (n =28).
3.3. Survival analysis
For survival analysis (OS and DFS) we assessed a cohort of 84 patients
with neuroendocrine carcinomas for whom follow up was available:
52 patients with NEBC and 32 patients with solid carcinomas with
NE component focally expressed. In the comparison of OS between
the two groups, the curve for the focal NE is worse, although
not statistically signiﬁcantly (p = 0.43). Moreover we have compared
patients with neuroendocrine tumors with a group of 2,745 control
cases; NE patients had signiﬁcantly larger tumor diameter (p = 0.04),
increased expression of hormone receptors (p <<0.001), and a lower
expression of the biomarkers erbB2 (p =0.002), Ki-67 (p < 0.001) and
p53 (p =0.005).
At the molecular level, our data agree with recent gene expression
proﬁling studies 62 that show NE as belonging to the Luminal A
molecular type. Indeed, therewas positivity for hormone receptors (in
our experience, on average ER=87% and PgR=75%), low expression
of Ki67 (14%) and c-erbB2 virtually absent (<1%). Because of this,
the prognosis for NEBC patients is reported to be good usually, in
accordance with our data, collected in an average follow up of 89
months. The 10-year survival of our 96 patients (NE+NEF) was 87%.
4. Discussion
NEBC shows clinical and biological characteristics more favorable
than the majority of breast cancers. This characteristic is observed
even in their prognosis. Considering the incidence of NEBC, which
nearly 1% of breast cancers, in our opinion it deserves the develop-
ment ofmore speciﬁc therapies, like other subtypes of breast cancer.
5. Conclusion
A primary challenge for future treatment of patients will be to dis-
tinguish between genes and pathways that drive cancer proliferation
and genes andpathways that havenoprimary role in thedevelopment
of cancer. The identiﬁcation of functional pathways that are enriched
for mutated genes will select subpopulations of patients that will
most likely be sensitive to chemotherapy or to biology-driven targeted
agents. Also, loco-regional treatment might become personalized
according to speciﬁc subtypes of breast cancer, in order to maximize
efﬁcacy while minimizing the extent of treatment. Anyway this
aim requires tailored treatment investigations through international
cooperation and should not just rely on information predominantly
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